Laboratory of Systems Pharmacology and Bioinformatics, Institut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Trends Pharmacol Sci. 2010 Jan;31(1):15-21. doi: 10.1016/j.tips.2009.10.008. Epub 2009 Dec 4.
G protein-coupled receptors (GPCRs) represent the major target for drug development. Although these receptors can activate their cognate G-proteins in a monomeric form, it is now recognized that they can assemble into dimers, or larger oligomers. However, the functional consequences of such receptor assembly remain elusive. Recent data revealed an 'asymmetric' organization of some dimers when activating heterotrimeric G-proteins, while a symmetric organization may be required for the activation of other signalling pathways. Here we describe a mathematical model taking these latest ideas into consideration, and report on the expected consequences of the activation of different signalling pathways. This model helps clarify data already published, and will certainly be helpful to further explain the functional significance of GPCR oligomerization. It may help develop more specific drugs targeting a specific signalling cascade.
G 蛋白偶联受体(GPCR)是药物开发的主要靶点。虽然这些受体可以以单体形式激活其同源 G 蛋白,但现在人们认识到它们可以组装成二聚体或更大的寡聚体。然而,这种受体组装的功能后果仍然难以捉摸。最近的数据揭示了一些二聚体在激活异三聚体 G 蛋白时的“不对称”组织,而对于其他信号通路的激活,可能需要对称的组织。在这里,我们描述了一个考虑到这些最新想法的数学模型,并报告了不同信号通路激活的预期后果。该模型有助于澄清已经发表的数据,并肯定有助于进一步解释 GPCR 寡聚化的功能意义。它可能有助于开发针对特定信号级联的更具特异性的药物。